P591: PRELIMINARY RESULTS OF A PHASE I STUDY OF CLIFUTINIB, A HIGHLY SELECTIVE, POTENT ORAL FLT-3 INHIBITOR, IN PATINETS WITH FLT3-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA. (23rd June 2022) - Yu, W.; Wei, X.; Ge, Z.; Li, Y.; Jiang, Z.; Yang, L.; Lin, L.; Yao, Y.; Deng, X.; Du, X.; Li, Y.; Chen, T.; et al.